NCT07452198

A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma

A Phase 3, Multicenter, Open-Label, Randomized Study Comparing GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy Including Lenalidomide and Proteasome Inhibitors

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 358 (estimated)
• Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to compare the efficacy of GR1803 Injection with daratumumab in combination with pomalidomide and dexamethasone (DPd).

Conditions

• Multiple Myeloma

Interventions

Type	Name	Description
DRUG	GR1803 injection	Participants received intravenous GR1803 injection at a dose of 180 ug per kilogram, which had been preceded by step-up doses of 10 and 30 ug per kilogram.
DRUG	Daratumumab	Participants received subcutaneous Daratumumab at a dose of 1800 mg.
DRUG	Pomalidomide	Participants received Pomalidomide at a dose of 4 mg on days 1 to 21 of each cycle (28 days).
DRUG	Dexamethasone	Participants received once-weekly dexamethasone at a dose of 40 mg (≤75 years) or 20 mg (\>75 years).

Timeline

• Start date: 2026-03-09
• Primary completion: 2029-03-01
• Completion: 2030-03-01
• First posted: 2026-03-05
• Last updated: 2026-03-25

Locations

1 site across 1 country: China